MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.67
+0.87
+12.79%
Pre Market: 7.55 -0.12 -1.56% 07:26 09/28 EDT
OPEN
7.00
PREV CLOSE
6.80
HIGH
8.11
LOW
6.81
VOLUME
3.64K
TURNOVER
--
52 WEEK HIGH
9.54
52 WEEK LOW
1.860
MARKET CAP
325.37M
P/E (TTM)
-325.0000
1D
5D
1M
3M
1Y
5Y
50 Biggest Movers From Yesterday
Gainers
Benzinga · 2h ago
31 Stocks Moving In Monday's Mid-Day Session
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to provide drone and rover software, hardware, and support for the Simulated Mars missi...
Benzinga · 19h ago
Is Corvus Pharmaceuticals a Good Healthcare Stock to Add to Your Portfolio?
StockNews.com · 1d ago
BRIEF-Tang Capital Partners Lp Reports 8.8% Passive Stake In Corvus Pharmaceuticals Inc
reuters.com · 5d ago
Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan
Zacks.com · 5d ago
Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial.
Benzinga · 6d ago
BRIEF-Corvus Pharmaceuticals Updates On Mupadolimab Programs In Oncology And Infectious Disease
reuters.com · 6d ago
Corvus Pharmaceuticals Announced Results Published Online in Medrxiv in 40 Patients From Covid-19 Randomized Controlled Study, Which Showed Primary and Secondary Endpoints Trend Toward More Favorable Outcome for Mupadolimab Treated Patients Vs. Placebo
Corvus Pharmaceuticals, Inc.
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRVS. Analyze the recent business situations of Corvus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
75.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRVS stock price target is 5.13 with a high estimate of 6.00 and a low estimate of 3.500.
High6.00
Average5.13
Low3.500
Current 7.67
EPS
Actual
Estimate
-0.040.260.550.85
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 76
Institutional Holdings: 27.18M
% Owned: 64.07%
Shares Outstanding: 42.42M
TypeInstitutionsShares
Increased
13
809.40K
New
4
3.65M
Decreased
17
734.49K
Sold Out
3
446.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.10%
Pharmaceuticals & Medical Research
-0.86%
Key Executives
Chairman/President/Chief Executive Officer/Director
Richard Miller
Chief Financial Officer/IR Contact Officer
Leiv Lea
Senior Vice President
William Jones
Senior Vice President
Mehrdad Mobasher
Independent Director
Ian Clark
Independent Director
Elisha Gould
Independent Director
Linda Grais
Independent Director
Edith Mitchell
Independent Director
Scott Morrison
Independent Director
Peter Thompson
No Data
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Webull offers kinds of Corvus Pharmaceuticals Inc stock information, including NASDAQ:CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.